Germion Therapeutics

Germion Therapeutics develops a novel class of metalloid-based antibiotics to address the growing challenge of antimicrobial resistance. The technology originates from an unexplored chemical space and has demonstrated antibacterial activity combined with favorable tolerability in preclinical models. By combining simple, scalable synthesis and a differentiated chemical approach, Germion aims to expand the limited pipeline by bringing new antibiotic classes. The company is advancing its compounds through early-stage development, strengthening intellectual property, and building a robust scientific and regulatory roadmap with the objective of enabling clinical development through partnerships or further funding.